Gilead relinquishes orphan drug designation for potential COVID-19 treatment

Ben Remaly

26 March 2020

Credit: Corona Borealis Studio/Shutterstock

Gilead Sciences has asked the US Food and Drug Administration to rescind an orphan drug designation for its experimental covid-19 treatment just days after the agency granted the status.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Ben Remaly

View full biography

Author | Editor, GCR USA

[email protected]

Tipline

Punching up: The Tipline for 2 December 2022
Satire only works when it's directed at the powerful. Federal Trade Commission chair Lina Khan feels the same way about antitrust enforcement. Speaking before the Organisation for Economic Co-operation and Development on Thursday, Khan said enforcers should use their prosecutorial discretion to pick cases that ensure they “punch up, don’t punch down”. Also in Tipline, the UK’s antitrust enforcer wants to stop one of its confidential decisions from being leaked as part of the …
Put me in coach: The Tipline for 1 December 2022
Sing When You're Winning: The Tipline for 30 November 2022